Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator

被引：9

作者：

Francia, Pietro ^{[1
]}

Ziacchi, Matteo ^{[2
]}

Adduci, Carmen ^{[1
]}

Ammendola, Ernesto ^{[3
]}

Pieragnoli, Paolo ^{[4
]}

De Filippo, Paolo ^{[5
]}

Rapacciuolo, Antonio ^{[6
]}

Rella, Valeria ^{[7
]}

Migliore, Federico ^{[8
]}

Viani, Stefano ^{[9
]}

Musumeci, Maria Beatrice ^{[1
]}

Biagini, Elena ^{[2
]}

Lovecchio, Mariolina ^{[10
]}

Baldini, Rossella ^{[1
]}

Falasconi, Giulio ^{[11
,12
]}

Autore, Camillo ^{[1
]}

Biffi, Mauro ^{[2
]}

Cecchi, Franco ^{[4
,7
]}

机构：

[1] Univ Sapienza, St Andrea Hosp, Dept Clin & Mol Med, Cardiol, Rome, Italy

[2] Univ Bologna, Inst Cardiol, Dept Expt Diagnost & Specialty Med, Policlin S Orsola Malpighi, Bologna, Italy

[3] Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Naples, Italy

[4] Univ Florence, Careggi Univ Hosp, Florence, Italy

[5] Papa Giovanni XXIII Hosp, Bergamo, Italy

[6] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy

[7] San Luca Hosp, Ist Auxol Italiano, Dept Cardiovasc Neural & Metab Sci, IRCCS, Milan, Italy

[8] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Padua, Italy

[9] Univ Hosp Pisa, Cardiothorac & Vasc Dept, Cardiol Div 2, Pisa, Italy

[10] Boston Sci, Milan, Italy

[11] Univ Barcelona, Campus Clin, Barcelona, Spain

[12] IRCCS Humanitas Res Hosp, Milan, Italy

来源：

EUROPACE | 2023年 / 25卷 / 09期

关键词：

Hypertrophic cardiomyopathy; Implantable cardioverter-defibrillator; Subcutaneous implantable cardioverter-defibrillator; Device-related complications; SUDDEN CARDIAC DEATH; CARDIOVERTER-DEFIBRILLATOR; TASK-FORCE; INAPPROPRIATE SHOCKS; EUROPEAN-SOCIETY; PREVENTION; OUTCOMES; THERAPY; ICD; ASSOCIATION;

D O I：

10.1093/europace/euad270

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims The implantable cardioverter-defibrillator (ICD) is a life-saving therapy in patients with hypertrophic cardiomyopathy (HCM) at risk of sudden cardiac death. Implantable cardioverter-defibrillator complications are of concern. The subcutaneous ICD (S-ICD) does not use transvenous leads and is expected to reduce complications. However, it does not provide bradycardia and anti-tachycardia pacing (ATP). The aim of this study was to compare appropriate and inappropriate ICD interventions, complications, disease-related adverse events and mortality between HCM patients implanted with a S- or transvenous (TV)-ICD.Methods and results Consecutive HCM patients implanted with a S- (n = 216) or TV-ICD (n = 211) were enrolled. Propensity-adjusted cumulative Kaplan-Meier curves and multivariate Cox proportional hazard ratios were used to compare 5-year event-free survival and the risk of events. The S-ICD patients had lower 5-year risk of appropriate (HR: 0.32; 95%CI: 0.15-0.65; P = 0.002) and inappropriate (HR: 0.44; 95%CI: 0.20-0.95; P = 0.038) ICD interventions, driven by a high incidence of ATP therapy in the TV-ICD group. The S- and TV-ICD patients experienced similar 5-year rate of device-related complications, albeit the risk of major lead-related complications was lower in S-ICD patients (HR: 0.17; 95%CI: 0.038-0.79; P = 0.023). The TV- and S-ICD patients displayed similar risk of disease-related complications (HR: 0.64; 95%CI: 0.27-1.52; P = 0.309) and mortality (HR: 0.74; 95%CI: 0.29-1.87; P = 0.521).Conclusion Hypertrophic cardiomyopathy patients implanted with a S-ICD had lower 5-year risk of appropriate and inappropriate ICD therapies as well as of major lead-related complications as compared to those implanted with a TV-ICD. Long-term comparative follow-up studies will clarify whether the lower incidence of major lead-related complications will translate into a morbidity or survival benefit. Graphical Abstract

引用

页数：9

共 50 条

[11] Use of a Primary Prevention Totally Subcutaneous Defibrillator in Hypertrophic Cardiomyopathy
Baez-Escudero, Jose L.
Beshai, John F.
Burke, Martin C.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2010, 3 (05): : 560 - 561
[12] Subcutaneous or Transvenous Defibrillator Therapy
Knops, Reinoud E.
Nordkamp, Louise R. A. Olde
Delnoy, Peter-Paul H. M.
Boersma, Lucas V. A.
Kuschyk, Juergen
El-Chami, Mikhael F.
Bonnemeier, Hendrik
Behr, Elijah R.
Brouwer, Tom F.
Kaab, Stefan
Mittal, Suneet
Quast, Anne-Floor B. E.
Smeding, Lonneke
van der Stuijt, Willeke
de Weger, Anouk
de Wilde, Koen C.
Bijsterveld, Nick R.
Richter, Sergio
Brouwer, Marc A.
de Groot, Joris R.
Kooiman, Kirsten M.
Lambiase, Pier D.
Neuzil, Petr
Vernooy, Kevin
Alings, Marco
Betts, Tim R.
Bracke, Frank A. L. E.
Burke, Martin C.
de Jong, Jonas S. S. G.
Wright, David J.
Tijssen, Jan G. P.
Wilde, Arthur A. M.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06): : 526 - 536
[13] Subcutaneous or Transvenous Defibrillator Therapy
Knops, Reinoud E.
van der Stuijt, Willeke
Smeding, Lonneke
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 678 - 679
[14] Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy?
Qin, Fen
Liu, Qiming
Liu, Zhenjiang
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 246 : 54 - 54
[15] Clinical performance of subcutaneous vs. transvenous implantable defibrillator in patients with ischemic cardiomyopathy: data from Monaldi Rhythm Registry
Russo, Vincenzo
Caturano, Alfredo
Bianchi, Valter
Rago, Anna
Ammendola, Ernesto
Papa, Andrea Antonio
Della Cioppa, Nadia
Guarino, Annamaria
Masi, Alessandro
D'Onofrio, Antonio
Golino, Paolo
Di Lorenzo, Emilio
Nigro, Gerardo
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2025, 12
[16] Clinical course and outcome of pregnancy in patients with hypertrophic cardiomyopathy
Fumagalli, C.
Sasso, L.
Zocchi, C.
Tassetti, L.
Celata, A.
Berteotti, M.
Mori, F.
Mecacci, F.
Livi, P.
Cappelli, F.
Baldini, K.
Tomberli, A.
Favilli, S.
Olivotto, I.
EUROPEAN HEART JOURNAL, 2021, 42 : 1782 - 1782
[17] Atrial fibrillation in hypertrophic cardiomyopathy: clinical implications of an early detection through implanted cardioverter defibrillator
Morgagni, R.
Sanniti, A.
Sergi, D.
Magliano, G.
Romeo, F.
EUROPEAN HEART JOURNAL, 2018, 39 : 276 - 276
[18] Who Should Receive the Subcutaneous Implanted Defibrillator? Timing Is Not Right to Replace the Transvenous Implantable Cardioverter Defibrillator
Acha, Moshe Rav
Milan, David
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2013, 6 (06): : 1246 - 1251
[19] Clinical outcome in patients with hypertrophic cardiomyopathy and implantable cardioverter defibrillator therapy
Schukro, Christoph
Rosenhek, Raphael
Pezawas, Thomas
Stix, Johannes
Kastner, Johannes
Wolzt, Michael
Schmidinger, Herwig
WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (15-16) : A36 - A37
[20] Clinical outcome following cardioverter defibrillator implantation in patients with hypertrophic cardiomyopathy
Lobo, TJ
Friedman, PA
Rea, RF
Munger, TM
Hammill, SC
Osborn, MJ
Packer, DL
Stanton, MS
Shen, WK
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) : 435A - 435A

← 1 2 3 4 5 →